UNSPSC 51391720: Butanefrine or ethylnorepinephrine

This classification denotes an adrenergic agent with the molecular formula C10H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6AY4VCZ0A, chemically known as 4-(2-amino-1-hydroxybutyl)-1,2-benzenediol but generally known as ethylnorepinephrine, which bears US NIH Compound Identifier 18538. European Medicines Agency schedules Ethylnorepinephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13768MIG.

Butanefrine or ethylnorepinephrine bears US NLM identifiers UMLS ID C0602107 and NCI Concept Code C75928. SMILES: CCC(C(C1=CC(=C(C=C1)O)O)O)N.

UNSPSC 51391720 Butanefrine or ethylnorepinephrine, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The code nominally covers a single active pharmaceutical ingredient, yet the recent opportunities tagged under it address naloxone procurement and direct-to-manufacturer prescription programs — products and service models that diverge substantially from the code's stated substance. State and local governments buying under this code designation are primarily health agencies and county health departments seeking opioid-reversal medications and pharmacy benefit management capabilities rather than butanefrine or ethylnorepinephrine specifically. Issuing bodies include county health systems and state health and human services commissions conducting procurement to support community health, addiction-response, and pharmacy cost-management initiatives.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County, Florida released an IFB (No. IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, with a two-year initial term and one-year renewal option on a fixed-fee basis. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, a preliminary market-intelligence effort preceding formal RFP development. The mismatch between the code name and actual procurement scope suggests either miscategorization in source data or a state-local taxonomy drift; the code appears inactive for its stated pharmaceutical substance.